ABSTRACT Stathmin (STMN1), a recognized oncoprotein upregulated in various solid tumors, promotes microtubule disassembly and modulates tumor growth and migration activity. However, the

mechanisms underlying the genetic regulation of STMN1 have yet to be elucidated. In the current study, we report that thyroid hormone receptor (THR) expression is negatively correlated with

STMN1 expression in a subset of clinical hepatocellular carcinoma (HCC) specimens. We further identified the _STMN1_ gene as a target of thyroid hormone (T3) in the HepG2 hepatoma cell line.

An analysis of STMN1 expression profile and mechanism of transcriptional regulation revealed that T3 significantly suppressed STMN1 mRNA and protein expression, and further showed that THR

downregulated by T3 in the liver. This T3-mediated suppression of STMN1 supports the theory that T3 plays an inhibitory role in HCC tumor growth, and suggests that the lack of normal THR

function leads to elevated STMN1 expression and malignant growth. SIMILAR CONTENT BEING VIEWED BY OTHERS REGULATION OF CANCER STEM CELL ACTIVITY BY THYROID HORMONE RECEPTOR Β Article 07

March 2022 THYROID HORMONE RECEPTOR Α1: A NOVEL REGULATOR OF THYROID CANCER CELL DIFFERENTIATION Article 26 August 2023 THYROID HORMONES INHIBIT TUMOR PROGRESSION AND ENHANCE THE ANTITUMOR

ACTIVITY OF LENVATINIB IN HEPATOCELLULAR CARCINOMA VIA REPROGRAMMING GLUCOSE METABOLISM Article Open access 08 March 2025 INTRODUCTION Thyroxine, also known as 3,3′,5-triiodo-L-thyronine

(T3), mediates numerous physiological processes, including ontogenesis, cell growth, cellular differentiation and metabolism, in nearly all mammalian tissues. The biological activity of T3

relies on binding to nuclear thyroid hormone receptors (THRs) belonging to the ligand-dependent transcriptional factor family, which maintain homeostasis by modulating expression levels of

various genes. Two human THR genes, TRα (_THRA_) and TRβ (_THRB_), are located on human chromosomes 17 and 3, respectively1. Different isoforms of THR (TRα1, TRα2/TRβ1 and TRβ2) are

generated by alternative RNA splicing or multiple promoter usage2. Moreover, THRs usually interact with retinoid X receptor (RXR) to form heterodimers that bind to thyroid hormone response

elements (TREs) within the promoter regions or introns of target genes to regulate their transcriptional activity3. Disorders of the thyroid gland are increasingly common endocrine

diseases4. The lack of T3 causes goiter and metabolic syndromes, such as mental retardation5. The liver expresses equal amounts of THRA and THRB, implying that T3 regulates gene expression

through transactivation6. To date, several studies have confirmed that hypothyroidism triggers hyperlipidemia, obesity and non-alcoholic steatohepatitis, the latter of which progresses to

liver cirrhosis and hepatocellular carcinoma (HCC) development7,8. A significantly increased risk of HCC development (up to 2–3 fold) has been reported in human adults with hypothyroidism9.

Moreover, studies on patients with chronic hepatitis C virus infection have suggested a correlation between lower T3 levels and thyroid papillary cancer10,11. Notably, chemical-induced liver

cancer in rats was shown to be markedly reduced in the presence of T312. These findings suggest a significant association of T3 malfunction and impaired liver function with the pathogenesis

of cancer. Analogously, aberrant THR expression or mutations have been reported in cases of severe resistance to thyroid hormone and are associated with developmental disease and cancer

progression. Genetic mutations in THRA and THRB were detected in 65% and 76% of HCCs, respectively13. A characterization of mutant THRs in the J7 human hepatocellular carcinoma cell line

revealed that mutated THRA binds TREs, but not T3, indicative of dominant-negative activity14,15. THRs play an important role in tumor progression, as evidenced by their aberrant expression

and mutation in other human cancers, including pituitary tumors, thyroid papillary cancer and renal clear-cell carcinomas16,17,18,19. Transgenic mice harboring a THRB mutation (THRBpv/pv)

isolated from patients with thyroid hormone resistance exhibit spontaneous induction of metastatic thyroid carcinomas20. Loss of functional THRs in mice leads to the development of

follicular thyroid cancer and metastases in the lung21. Moreover, THRB overexpression potently represses tumor metastasis22. These findings collectively suggest that loss of normal

regulation of THRs enhances tumor progression, supporting a tumor-suppressor function of these receptors. Conversely, however, other studies have indicated that THRs enhance tumor

progression. For instance, T3 has been reported to stimulate the proliferation of various cancer cell types, including pituitary-derived cancer, breast cancer, prostate cancer, and

glioma23,24,25,26. Previous experiments by our group showed that T3 suppresses hepatoma cell growth by prolonging the G0/G1 phase while inducing cell migration in association with enhanced

matrix metallopeptidase (MMP) activity27,28. Thus, the complex roles of T3/THR in tumorigenesis appear to reflect distinct, tissue-specific genetic backgrounds and definitions of oncogenic

roles. The details of the regulatory mechanisms involved in these oncogenic processes remain to be established. Stathmin (STMN1, also known as oncoprotein 18 [OP18]) is a 149-amino-acid,

cytosolic protein that is highly conserved among vertebrates29,30. STMN1 is highly expressed in various cancers and has been characterized as an oncogenic protein31. The predominant

molecular function of STMN1 is regulation of microtubule dynamics. The phosphorylated C-terminal domain of STMN1 physically interacts with unpolymerized tubulin dimers, influencing the

dynamics of microtubule formation32,33. STMN1 prevents assembly and promotes disassembly of microtubules, thus participating in microtubule-related cellular functions, such as cell

proliferation and migration. STMN1 is downregulated by p53 and regulates cell cycle arrest at the G2/M and G1/S checkpoints34,35. Moreover, STMN1 interacts with p27 and Cdk2/Cdk5, leading to

enhanced protein phosphorylation and consequent tubulin stabilization and inhibition of cell migration36. These findings support a crucial role of STMN1 in cancer growth and mobility.

Accumulating evidence suggests that STMN1 regulates microtubulin assembly and consequently tumorigenesis, but the mechanisms underlying the regulation of _STMN1_ gene expression remain

unknown. Here, we found that THR and STMN1 are negatively correlated at RNA and protein levels in clinical specimens. We further determined that STMN1 expression was markedly repressed by T3

at the transcriptional level. Moreover, cell growth was inhibited by STMN1 depletion as well as T3 treatment, confirming that T3 plays a role in suppression of tumor growth. RESULTS

NEGATIVE CORRELATION OF THRA AND STMN1 EXPRESSION IN CLINICAL LIVER CANCER SPECIMENS Previous studies have reported THR-mediated suppression of cell proliferation28 and loss of THR

expression in clinical samples of HCC37,38. In contrast, several lines of evidence indicate that STMN1 is upregulated in cancers31. To gain insight into the biological significance of these

expression patterns, we compared the relative abundance of THR isoforms (THRA, THRB) and STMN1 proteins in clinical HCC specimens (Fig. 1A). Immunohistochemical findings revealed that

expression of THRs was markedly decreased in tumor specimens, whereas STMN1 levels were enhanced (Fig. 1B). Moreover, expression of THRA, but not THRB, was negatively correlated with that of

STMN1 in patients (Fig. 1C and D). To further clarify the negative correlation between specific THR isoforms and STMN1, we analyzed three public datasets from Oncomine (Fig. 1E–J). Notably,

THRA and THRB mRNA expression were decreased, whereas expression of STMN1 was enhanced, in tumor specimens (Fig. 1E,G and I). Importantly, the negative correlation between STMN1 and THRA

was stronger than that between STMN1 and THRB (Fig. 1F,H and J). T3 SUPPRESSES STMN1 EXPRESSION IN HEPG2 CELL LINES Next, we overexpressed THRA in HepG2 cells, which express low levels of

endogenous THRs (Fig. 2A and S1A). We then verified suppression of STMN1 mRNA expression by T3 in THRA-overexpressing HepG2 cells using quantitative reverse transcription-polymerase chain

reaction (qRT-PCR) (Fig. 2B, S1B and S1C). After 72 h in the presence of T3, STMN1 mRNA levels were less than 10% of control levels (fold-repression values were normalized to those in the

absence of T3 at each time point). The effects of T3 on endogenous STMN1 mRNA levels in THRA-overexpressing cells were further analyzed by Northern blotting, which confirmed that STMN1 mRNA

levels were repressed by T3 (Fig. 2C, right panel). Of note, qRT-PCR analysis shows higher sensitivity that STMN1 mRNA levels have been reduced to 20% in 48 h. Next, we examined whether T3

exerts an inhibitory effect on STMN1 protein expression. Immunoblot analyses revealed that STMN1 protein was markedly suppressed by T3 in cells ectopically expressing THR compared with that

in cells devoid of THR (Fig. 2D; -THRA, -THRB and empty vector-Neo, Supplementary Fig. S1D and E; -THRA and empty vector-Neo, respectively). These data collectively demonstrate that T3

suppresses STMN1 mRNA and protein expression in a concentration- and THR-dependent manner. T3 REPRESSES STMN1 EXPRESSION AT THE TRANSCRIPTIONAL LEVEL Next, we determined whether the

repression of _STMN1_ gene expression by T3 is attributable to THR-mediated transcriptional regulation. To this end, we created a promoter-luciferase reporter construct by cloning a 3-kb

genome sequence upstream of the _STMN1_ start codon into a pGL3-Luc vector and performed luciferase assays. As shown in Fig. 3A, the 3-kb upstream region (construct I, positions −2891 to +1)

was involved in mediating T3-induced repressive activity (Fig. 3A, upper panel). A serial deletion analysis of the _STMN1_ promoter further revealed that the −701 to +1 fragment contains

the element responsible for T3 suppression of _STMN1_ transcription (Fig. 3A, construct V). Further deletion impaired _STMN1_ promoter activity, suggesting that these additionally deleted

regions might be responsible for native RNA polymerase II recognition (Supplementary Fig. S2). Accordingly, the −701 to +1 region and serially truncated fragments were subcloned into a

pA3tk-Luc vector containing a minimum thymidine kinase promoter to provide basal transcriptional activity (Fig. 3A, constructs VI–X). The transcriptional activity of −100 to +1 as well as

−701 to +1 regions was suppressed by T3 (constructs VI and IX, respectively). Furthermore, T3 suppression of transcriptional activity was blunted in the absence of the −100 to +1 fragment

(Fig. 3A, construct X, −701 to −101, and construct XI, −2891 to −101). Collectively, these data indicate that a suppressive TRE is present upstream of the _STMN1_ start codon and mediates

negative regulation of _STMN1_ transcription by T3. Since THRs act as nuclear transcription regulators, we examined whether THR directly targets the _STMN1_ promoter to downregulate _STMN1_

transcription. Experiments using the protein synthesis inhibitor, cycloheximide (CHX), showed that STMN1 mRNA levels remained suppressed upon T3 treatment in the absence of _de novo_ protein

synthesis (Fig. 3B). Quantification of these results revealed that co-treatment with CHX suppressed STMN1 mRNA levels to an extent similar to that of T3 treatment alone (Fig. 3B, right

panel). These data imply that THR regulates the _STMN1_ promoter directly and not through an intermediate transcription factor. If this were not the case, the intermediate transcription

factor protein should be inhibited by CHX, resulting in impaired T3 repression of _STMN1_ expression. To validate specific THR binding to the STMN1 genome, we performed chromatin

immunoprecipitation (ChIP) assays. These assays revealed a THR-associated signal in the upstream element (positions −101 to +1) of _STMN1_ (Fig. 3C, lane 3; compare to IgG control in lane

2). This fragment was additionally pulled down by RXR, which dimerizes with THR (Fig. 3C, lane 4), suggesting that THR and RXR co-bind this sequence to exert repressive activity. On the

basis of these findings, we suggest that THR physically binds this upstream element, leading to suppression of _STMN1_ transcription by T3. Furthermore, in view of previous and present

results, we speculate that STMN1 is negatively regulated by T3; thus, its expression levels are elevated in THR-deficient HCCs. DEPLETION OF STMN1 IN J7 CELLS SUPPRESSES CELL PROLIFERATION

We further examined the effects of STMN1 knockdown on cell growth. Because HepG2 cells are inadequate for tumor xenograft models, we chose J7 cells for proliferation assays and xenograft

transplantation. Silencing of STMN1 in J7 cells by transduction with a lentivirus expressing small hairpin RNA (shRNA; clones #37 and #94) against STIMN1 led to marked suppression of STMN1

expression and growth of J7 liver cells compared with cells transduced with control lentivirus shRNA targeting firefly luciferase (Fig. 4A and B). Only a few colonies were detected in

colony-formation assays (Fig. 4C). In contrast, cell viability was not significantly reduced by knockdown of STMN1 (Fig. 4D). These findings indicate that STMN1 depletion significantly

reduces cell growth. To confirm this phenomenon, we established a heterotopic xenograft model to test tumorigenesis potential _in vivo_. STMN1-knockdown cells and parental control cells were

transplanted in parallel in the dorsal skin of nude mice (Fig. 5A). Notably, tumor growth was largely reduced in regions containing STMN1-knockdown cells, but was maintained in regions

containing shLuc control cells (Fig. 5B,C and D; n = 4), suggesting that STMN1 is crucial for tumor cell growth. STMN1 KNOCKDOWN CAUSES CELL CYCLE REDISTRIBUTION To further investigate the

molecular mechanism underlying STMN1-regulated cell growth, we analyzed the cell cycle distribution of parental and STMN1-knockdown J7 cells. Flow cytometry analyses indicated that the G2/M

phase population was expanded in STMN1-knockdown cells, whereas the G1 phase population was reduced (Fig. 6A). Quantification of these results confirmed a 2-fold increase in the G2/M

population in STMN1-knockdown cells compared with the Luc-knockdown control group (Fig. 6B). Moreover, STMN1 depletion was accompanied by increased levels of cyclin B and decreased levels of

cyclin D, which modulate cell-cycle progression (Fig. 6C). These findings provide evidence for changes in cell-cycle progression upon suppression of STMN1 expression. Accordingly, we

speculate that G2/M phase progression is retarded by knockdown of STMN1, leading to reduced cell proliferation. T3-MEDIATED SUPPRESSION OF STMN1 CONTRIBUTES TO CELL GROWTH ARREST To further

investigate the relevance of STMN1 in T3-mediated repression of cell growth, we restored STMN1 levels in HepG2-THRA cells by stably expressing STMN1-EGFP (Fig. 7A). T3 repressed cell growth

through an increase in the G1 phase population and a reduction in the G2/S phase population (Fig. 7B–D); it also suppressed both cyclin B and cyclin A protein levels (Fig. 7E). In contrast,

ectopic expression of STMN1 increased cell growth and expanded the G2 phase population in the presence of T3, and reduced the G1 phase population and caused accumulation of cyclin B (Fig.

7B–E). These data further confirm that STMN1 is involved in T3-induced cell growth arrest. We conclude that STMN1, an essential protein for tumorigenic growth and cell-cycle progression, is

inhibited by T3 at the transcriptional level, reflecting the negative correlation between the expression patterns of these proteins in clinical liver cancer specimens. DISCUSSION The present

study confirmed that STMN1 is highly expressed in clinical HCC samples39. Our results further indicate that THR down-regulates STMN1 expression and show that its expression is negatively

correlated with that of STMN1 in HCC, supporting the role of THR as a tumor suppressor. These results also establish THR as a new transcriptional regulator of _STMN1_ gene expression.

Notably, previous reports have indicated that both T3 treatment and STMN1 knockdown suppress cell growth28,39,40. However, the opposite changes in the cell cycle distribution caused by T3

treatment and STMN1 knockdown reveal differential regulation by these two interventions. We speculate that T3 treatment reduces the proliferation rate by causing accumulation of cells in G1

phase. By contrast, STMN1-knockdown cells lack normal microtubule turnover, leading to retardation in G2/M phase progression. This finding is in accord with previous reports41,42. However,

G1 arrest has also been observed in STMN1-depleted gastric tumor cell lines43. These inconsistencies in cell cycle regulation reflect the different mechanisms of tumor proliferation in which

STMN1 participates44. Our molecular evidence further revealed the cyclin B protein is elevated by STMN1 knockdown, whereas cyclin D is repressed. STMN1 rescue experiments designed clarify

the role of STMN1 in T3-induced cell growth arrest confirmed that STMN1 partially restores T3 effects on cell growth, cell-cycle redistribution and expression of cyclins. These data also

suggest that T3 acts at least in part through STMN1 to repress cell proliferation. However, the detailed molecular mechanism remains to be elucidated. A previous investigation showed that,

in normal liver subjected to partial hepatectomy, STMN1 expression is elevated in proliferating hepatocytes, but is silenced in resting hepatocytes, leading to the proposal that STMN1

expression is reversible and participates in tissue-specific proliferation–differentiation switching45. Other studies have revealed an oncogenic role of STMN1 based on its expression

profiles in patients or effects of manipulating its expression on cellular tumorigenicity39,40,46. Silencing of STMN1 expression in the HCC cell line, HCCLM3, was shown to significantly

reduce cell proliferation, adhesion and invasion, and trigger apoptosis40. Exogenous expression of E2F1 and the transcription factor DP-1 (TFDP1) has been shown to induce STMN1 mRNA

expression46. Moreover, overexpression of STMN1 results in microtubule disassembly and is associated with formation of binucleated cells39. These data collectively indicate that THR-mediated

suppression of STMN1 is required for normal liver maintenance. Impairment of this process may lead to constitutive STNM1 expression, and consequently, hepatic carcinogenesis. T3 actions

also extend to microtubules—the major cytoskeletal targets of STMN1—which are essential for internal vesicle transport and nervous system differentiation. Several studies have revealed that

T3 regulates microtubule organization and is involved in microtubule-associated cell physiology47,48. Specifically, the rate of microtubule assembly _in vitro_ is reduced in hypothyroid rats

and restored upon administration of physiological levels of T347. Notably, experiments using granulosa cells have shown that T3 dramatically reduces the effects of paclitaxel, a microtubule

inhibitor used for disruption of mitotic microtubule assembly and cancer therapy48. Considered in this context, our observations suggest that T3 might regulate microtubule network assembly

through repression of STMN1 expression. CONCLUSIONS In summary, we have provided evidence that T3 suppresses proliferation via transcriptional regulation of STMN1 expression. Moreover,

T3-regulated STMN1 expression may be associated with HCC malignancy. MATERIALS AND METHODS CELL CULTURE Human HCC cell lines were cultured in Dulbecco’s modified Eagle’s medium supplemented

with 10% (v/v) fetal bovine serum at 37 °C in a humidified 5% CO2 incubator. T3-depleted serum was prepared as described previously49. Briefly, an aliquot of serum (50 ml) was incubated with

2.2 g AG 1-X8 resin that had been washed three times with distilled, deionized water (15 min each), pelleted by brief centrifugation, and sterilized by autoclaving. T3 was depleted three

times for at least 5 h each and filtered using a 0.22-μm filter. QRT-PCR Total RNA was extracted using TRIzol (Invitrogen, 10296-028), as described previously50. cDNA was generated from 4 μg

of purified total RNA using the SuperscriptIII kit for RT-PCR (Invitrogen). qRT-PCR was performed in a 15-μl reaction mixture containing 50 nM forward and reverse primers, 1× SYBR Green

reaction mix (Applied Biosystems, 4309155) and 48 μg template, according to a previously described protocol50. The sequences of forward (q-STMN1-F) and reverse (q-STMN1-R) primers used were

5′-GTG GTC AGG CGG CTC GGA CTG-3′ and 5′-CTC TCG TTT CTC AGC CAG CTG C-3′, respectively. NORTHERN BLOTTING Cellular RNA was denatured by heating at 75 °C for 15 min and then chilled on ice

for 5 min. Denatured RNAs were resolved on a 1.2% agarose gel and transferred to a nylon membrane (Amersham Bioscience, UK) overnight. The membrane was cross-linked and blocked by

prehybridization in the presence of 250 μg/ml single-strand DNA for at least 8 h. α-32P-dCTP* was incorporated into the STMN1 probe by PCR. The sequences of forward (STMN1-F) and reverse

(STMN1-R) primers used were 5′-ATG GCT TCT TCT GAT ATC-3′ and 5′-TTA GTC AGC TTC AGT CTC-3′, respectively. The membrane was incubated with radiolabeled probe at 42 °C for 18 h. After a brief

wash, the remaining isotope signal was detected with X-ray film (Amersham Bioscience). IMMUNOHISTOCHEMICAL STAINING Tumor tissue microarrays were purchased from Taiwan Liver Cancer Network

(TCLN) and constructed to contain 115 normal liver tissues and 115 hepatocellular carcinoma samples. The staining score (Quick score) was calculated using the following formula: Staining

intensity was rate on a 0 to 3 scale, where 0 is negative, 1 is weak, 2 is moderate and 3 is strong; the area percentage reflects the degree of positive staining51. This study was approved

by the Institutional Review Board of Chang Gung Medical Center Human Ethics Committee (IRB No: 99-3588B). The study subjects provided written informed consent, and all methods were carried

out in accordance with the approved guidelines. SDS-PAGE AND IMMUNOBLOT ANALYSIS Total cell extracts were purified as described previously50. Equal amounts of protein were resolved by sodium

dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a PVDF (polyvinylidene difluoride) membrane using a semi-dry transfer system. The membrane was blocked by

incubating with 5% non-fat milk dissolved in phosphate-buffered saline containing 0.1% Tween-20 (PBST) for 1 h, and then was incubated with the appropriately diluted primary antibody at 4 °C

overnight. After washing with PBST, the membrane was incubated with the appropriate secondary antibody for 2 h at room temperature. Immune complexes were developed by chemiluminescence

using an enhanced chemiluminescence (ECL) detection kit (Amersham, RPN2232)50. ANTIBODIES AND REAGENTS The following antibodies and reagents were used: rabbit polyclonal anti-STMN1

(Calbiochem, 569391), rabbit polyclonal anti-THRA (GeneTex, GTX25621), mouse monoclonal anti-THRB (Santa Cruz, SC-737), mouse monoclonal anti-β-actin (Chemicon, MAB1501R), rabbit monoclonal

anti-cyclin B1 (Abcam, ab32053), rabbit monoclonal anti-cyclin A (Abcam, ab185619), rabbit monoclonal anti-cyclin D1 (Epitomics, 4202-1), mouse monoclonal anti-β-tubulin (Chemicon, MAB3408),

AG 1-X8 resin (Bio-Rad, 140-1451), T3 (Sigma-Aldrich, T2752), and cycloheximide (Sigma-Aldrich, C7698). Mouse monoclonal anti-THR (C4) was a gift from Sheue-yann Cheng (National Cancer

Institute). PLASMID CONSTRUCTION Constructs containing potential THR-regulated sites of the _STMN1_ promoter were generated by PCR-amplification of an upstream region of the _STMN1_ gene

corresponding to nucleotides −2891 to +1 (where +1 corresponds to the AUG initiation site) and serially deleted fragments, and subcloning them into pGL3-Luc or pA3tk-Luc plasmids. The primer

sequences and restriction sites used were as follows: STMN1(−2891)-_Kpn_I-F: 5′-AAATAAGGTACCTCAAAGCAGGTGTCTTGGTG-3′, STMN1(−2241)-_Kpn_I-F: 5′-AAATAAGGTACCGTCTTAGGCACCCATGTGGG-3′,

STMN1(−1943)-_Kpn_I-F: 5′-AAATAAGGTACCCATTGTCCTCCTGCCCTCCG-3′, STMN1(−1191)-_Kpn_I-F: 5′-AAATAAGGTACCAGCTTGGGTGGCGGCAGGTT-3′, STMN1(−701)-_Kpn_I-F: 5′-AAATAAGGTACCGGTACTAGCTGGCGTCTACA-3′,

STMN1(−450)-_Kpn_I-F: 5′-AAATAAGGTACCCAATGAGTTGTAGGCAGTAT-3′, STMN1(−250)-_Kpn_I-F: 5′-AAATAAGGTACCATATTCAGGTCATATTTCCC-3′, STMN1(−100)-_Kpn_I-F: 5′-ATAAGGTACCAAAGAAAGTGATTGCATGTTTT-3′,

STMN1(+1)-_Nhe_I-R: 5′-ACTATCGCTAGCTGGTGAATAGAAGACAAGCG-3′, STMN1(−101)-_Nhe_I-R: 5′-ACTATCGCTAGCGCCTTTCTATATGTCAT-3′. The STMN1-EGFP fusion plasmid was generated by first PCR-amplifying

STMN1 fragments and enhanced green fluorescent protein (EGFP) using primer pairs with the indicated sequences and incorporated restriction sites: STMN1-_Bam_HI-F, 5′-AAT CGG ATC CAT GGC TTC

TTC TGA TAT CCA GG-3′ (forward) and STMN1-EGFP-R, 5′-CCC TTG CTC ACC ATG TCA GCT TCA GTC TCG TCA GCA G-3′ (reverse); and EGFP-STMN1-F, 5′-CTG CTG ACG AGA CTG AAG CTG ACA TGG TGA GCA AGG G-3′

(forward) and EGFP-_Hin_dIII-R, 5′-GAT CAA GCT TTT ACT TGT ACA GCT CGT CCA TG-3′ (reverse). STMN1-EGFP was conjugated by mixing the two PCR products and performing a further extension step,

followed by subcloning into the pcDNA3.1/Hygro plasmid. PROMOTER-REPORTER AND CHIP ASSAYS HepG2-THRA cells were transfected overnight with _STMN1_ promoter vectors using the TurboFect

reagent (Thermo Fisher Scientific, R0531). Transfected cells were incubated in the presence or absence of T3 for an additional 48 h. After treatment, cells were lysed for the detection of

firefly luciferase activity (Promega, E1960). ChIP assays were performed as described previously52. Briefly, HepG2-THRA cells were fixed to cross-link DNA-protein complexes, and sonicated on

ice to obtain bulk DNA fragments with a size range of ~200–400 bp. THR- or RXRA-binding DNA was immunoprecipitated with the corresponding antibody, and complex crosslinking was reversed by

heating at 65 °C overnight. Targeted elements were detected by amplifying purified DNA fragments using primer pairs specific for the STMN1 TRE. The glyceraldehyde 3-phosphate dehydrogenase

(GAPDH) promoter region was used as a negative control. The following primer pairs were employed to detect specific promoter regions: ChIP-STMN1-F, 5′-AAA GAA AGT GAT TGC ATG TTT TTG AAA

ATC-3′ (STMN1 forward) and ChIP-STMN1-R, 5′-TGG TGA ATA GAA GAC AAG CGA CAG-3′ (STMN1 reverse); ChIP-GAPDH-F, 5′-CAA GGC TGA GAA CGG GAA GC-3’ (GAPDH forward) and ChIP-GAPDH-R, 5′-AGG GGG

CAG AGA TGA TGA CC-3′ (GAPDH reverse). KNOCKDOWN AND OVEREXPRESSION OF STMN1 For knockdown of endogenous STMN1, J7 cells were infected with lentivirus expressing shRNA targeting STMN1. The

pLKO.1 shLuc (control) and pLKO.1 shSTMN1 expression vectors were obtained from the National RNA Interference Core Facility (Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan).

Clones TRCN0000072243 and TRCN0000160037 correspond to shLuc and shSTMN1, respectively. For overexpression of STMN1, HepG2-THRA cells were transfected with an STMN1-EGFP expression plasmid.

EGFP-positive cells were further enriched by flow cytometry. PROLIFERATION AND COLONY-FORMATION ASSAYS For analysis of cell proliferation, 1 × 105 cells were seeded in wells of a 6-well

plate. Viable cells were trypsinized and counted on the indicated days. Colony-formation activity was analyzed by seeding 2 × 103 cells in 6-well plates for 14 d. After incubating for 2

weeks, colonies were fixed and stained with crystal violet. Colony numbers and occupied areas were scanned and measured using ImageJ software. MURINE TUMOR-PROGRESSION MODEL SCID mice were

used to assess the _in vivo_ growth potential of J7-shSTMN1-derived tumors. Briefly, J7-shLuc and J7-shSTMN1 cells (1 × 106) were suspended in 150 μl of PBS and injected into the dorsal skin

of mice (left, shLuc; right, shSTMN1). After 2 weeks, visible tumors were measured every 2–3 d. Tumor volume was calculated using the following formula: Xenograft tumors were subsequently

dissected and individually weighed. Animal care procedures were in accordance with the Chang-Gung Institutional Animal Care and Use Committee Guide for the Care and Use of Laboratory Animals

(CGU08-05), and all methods were approved by the Chang-Gung Institutional Animal Care and Use Committee. FLOW CYTOMETRY For cell-cycle analysis, cells were harvested by trypsin digestion

and fixed in 75% ethanol for at least 1 h at −20 °C. Cells were then treated with 0.5% Triton X-100 and 0.05% RNase A for 1 h at 37 °C. Thereafter, nuclear DNA was incubated with 50 μg/ml

propidium iodide stain for 20 min at 4 °C, and cells were analyzed on a FACSCalibur flow cytometer (Becton Dickinson Immunocytometry Systems, CA, USA). STATISTICAL ANALYSIS Values are

expressed as means ± s.e.m. Statistical analyses of data were performed using Student’s t-test or one-way analysis of variance (ANOVA), as appropriate. A _P_- value < 0.05 was considered

significant. ADDITIONAL INFORMATION HOW TO CITE THIS ARTICLE: Tseng, Y.-H. _et al_. Thyroid hormone suppresses expression of stathmin and associated tumor growth in hepatocellular carcinoma.

_Sci. Rep._ 6, 38756; doi: 10.1038/srep38756 (2016). PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional

affiliations. REFERENCES * Lazar, M. A. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev 14, 184–193 (1993). CAS  PubMed  Google Scholar  * Cheng, S. Y. Multiple

mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rev Endocr Metab Disord 1, 9–18 (2000). CAS  PubMed  Google Scholar  * Dong, H. et al. Identification

of thyroid hormone receptor binding sites and target genes using ChIP-on-chip in developing mouse cerebellum. PLoS One 4, e4610 (2009). ADS  PubMed  PubMed Central  Google Scholar  *

Harris, K. B. & Pass, K. A. Increase in congenital hypothyroidism in New York State and in the United States. Mol Genet Metab 91, 268–277 (2007). CAS  PubMed  Google Scholar  * Forrest,

D., Reh, T. A. & Rusch, A. Neurodevelopmental control by thyroid hormone receptors. Curr Opin Neurobiol 12, 49–56 (2002). CAS  PubMed  Google Scholar  * Chamba, A. et al. Expression and

function of thyroid hormone receptor variants in normal and chronically diseased human liver. J Clin Endocrinol Metab 81, 360–367 (1996). CAS  PubMed  Google Scholar  * Loria, P., Carulli,

L., Bertolotti, M. & Lonardo, A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 6, 236–247 (2009). CAS  PubMed  Google Scholar  *

Pearce, E. N. Update in lipid alterations in subclinical hypothyroidism. J Clin Endocrinol Metab 97, 326–333 (2012). CAS  PubMed  Google Scholar  * Hassan, M. M. et al. Association between

hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 49, 1563–1570 (2009). PubMed  PubMed Central  Google Scholar  * Antonelli, A. et al.

Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab 5, 26–34 (2009). CAS  PubMed  Google Scholar  * Moustafa, A. H., Ali, E. M., Mohamed, T. M. &

Abdou, H. I. Oxidative stress and thyroid hormones in patients with liver diseases. Eur J Intern Med 20, 703–708 (2009). CAS  PubMed  Google Scholar  * Perra, A., Kowalik, M. A., Pibiri, M.,

Ledda-Columbano, G. M. & Columbano, A. Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype.

Hepatology 49, 1287–1296 (2009). CAS  PubMed  Google Scholar  * Lin, K. H., Shieh, H. Y., Chen, S. L. & Hsu, H. C. Expression of mutant thyroid hormone nuclear receptors in human

hepatocellular carcinoma cells. Mol Carcinog 26, 53–61 (1999). CAS  PubMed  Google Scholar  * Lin, K. H. et al. Dominant negative activity of mutant thyroid hormone alpha1 receptors from

patients with hepatocellular carcinoma. Endocrinology 138, 5308–5315 (1997). CAS  PubMed  Google Scholar  * Lin, K. H. et al. Identification of naturally occurring dominant negative mutants

of thyroid hormone alpha 1 and beta 1 receptors in a human hepatocellular carcinoma cell line. Endocrinology 137, 4073–4081 (1996). CAS  PubMed  Google Scholar  * Ando, S. et al. Aberrant

alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance. Mol Endocrinol 15, 1529–1538 (2001). CAS  PubMed  Google Scholar  *

Master, A. et al. Untranslated regions of thyroid hormone receptor beta 1 mRNA are impaired in human clear cell renal cell carcinoma. Biochim Biophys Acta 1802, 995–1005 (2010). CAS  PubMed

  Google Scholar  * Puzianowska-Kuznicka, M., Krystyniak, A., Madej, A., Cheng, S. Y. & Nauman, J. Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin

Endocrinol Metab 87, 1120–1128 (2002). CAS  PubMed  Google Scholar  * Rosen, M. D. & Privalsky, M. L. Thyroid hormone receptor mutations found in renal clear cell carcinomas alter

corepressor release and reveal helix 12 as key determinant of corepressor specificity. Mol Endocrinol 23, 1183–1192 (2009). CAS  PubMed  PubMed Central  Google Scholar  * Suzuki, H.,

Willingham, M. C. & Cheng, S. Y. Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid

12, 963–969 (2002). CAS  PubMed  Google Scholar  * Zhu, X. G., Zhao, L., Willingham, M. C. & Cheng, S. Y. Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic

follicular thyroid carcinoma. Oncogene 29, 1909–1919 (2010). CAS  PubMed  PubMed Central  Google Scholar  * Martinez-Iglesias, O. et al. Thyroid hormone receptor beta1 acts as a potent

suppressor of tumor invasiveness and metastasis. Cancer Res 69, 501–509, doi: 10.1158/0008-5472.CAN-08-2198 (2009). Article  CAS  PubMed  Google Scholar  * Barrera-Hernandez, G., Park, K.

S., Dace, A., Zhan, Q. & Cheng, S. Y. Thyroid hormone-induced cell proliferation in GC cells is mediated by changes in G1 cyclin/cyclin-dependent kinase levels and activity.

Endocrinology 140, 5267–5274 (1999). CAS  PubMed  Google Scholar  * Davis, F. B. et al. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res

66, 7270–7275 (2006). CAS  PubMed  Google Scholar  * Hall, L. C., Salazar, E. P., Kane, S. R. & Liu, N. Effects of thyroid hormones on human breast cancer cell proliferation. J Steroid

Biochem Mol Biol 109, 57–66 (2008). CAS  PubMed  Google Scholar  * Tsui, K. H., Hsieh, W. C., Lin, M. H., Chang, P. L. & Juang, H. H. Triiodothyronine modulates cell proliferation of

human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2. Prostate 68, 610–619 (2008). CAS  PubMed  Google Scholar  * Chen, R. N., Huang, Y. H., Yeh, C. T., Liao,

C. H. & Lin, K. H. Thyroid hormone receptors suppress pituitary tumor transforming gene 1 activity in hepatoma. Cancer Res 68, 1697–1706 (2008). CAS  PubMed  Google Scholar  * Yen, C.

C. et al. Mediation of the inhibitory effect of thyroid hormone on proliferation of hepatoma cells by transforming growth factor-beta. J Mol Endocrinol 36, 9–21 (2006). CAS  PubMed  Google

Scholar  * Jiang, X. et al. Molecular cloning and expression analysis of evolutionarily conserved stathmin from Gekko japonicus spinal cord. Indian J Biochem Biophys 46, 289–293 (2009). CAS

  PubMed  Google Scholar  * Maucuer, A., Moreau, J., Mechali, M. & Sobel, A. Stathmin gene family: phylogenetic conservation and developmental regulation in Xenopus. J Biol Chem 268,

16420–16429 (1993). CAS  PubMed  Google Scholar  * Rana, S., Maples, P. B., Senzer, N. & Nemunaitis, J. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev

Anticancer Ther 8, 1461–1470 (2008). CAS  PubMed  Google Scholar  * Belmont, L. D. & Mitchison, T. J. Identification of a protein that interacts with tubulin dimers and increases the

catastrophe rate of microtubules. Cell 84, 623–631 (1996). CAS  PubMed  Google Scholar  * Horwitz, S. B. et al. The microtubule-destabilizing activity of metablastin (p19) is controlled by

phosphorylation. J Biol Chem 272, 8129–8132 (1997). CAS  PubMed  Google Scholar  * Johnsen, J. I. et al. p53-mediated negative regulation of stathmin/Op18 expression is associated with

G(2)/M cell-cycle arrest. Int J Cancer 88, 685–691 (2000). CAS  PubMed  Google Scholar  * Murphy, M. et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases,

mediated by interaction with mSin3a. Genes Dev 13, 2490–2501 (1999). CAS  PubMed  PubMed Central  Google Scholar  * Nadeem, L. et al. Cytoplasmic mislocalization of p27 and CDK2 mediates the

anti-migratory and anti-proliferative effects of Nodal in human trophoblast cells. J Cell Sci 126, 445–453 (2013). CAS  PubMed  Google Scholar  * Frau, C. et al. Local hypothyroidism favors

the progression of preneoplastic lesions to hepatocellular carcinoma in rats. Hepatology 61, 249–259, doi: 10.1002/hep.27399 (2015). Article  CAS  PubMed  Google Scholar  * Liao, C. H. et

al. Dickkopf 4 positively regulated by the thyroid hormone receptor suppresses cell invasion in human hepatoma cells. Hepatology 55, 910–920 (2012). CAS  ADS  PubMed  Google Scholar  *

Hsieh, S. Y. et al. Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog 49, 476–487 (2010). CAS 

PubMed  Google Scholar  * Gan, L. et al. Up-regulated expression of stathmin may be associated with hepatocarcinogenesis. Oncol Rep 23, 1037–1043 (2010). CAS  PubMed  Google Scholar  * Luo,

X. N., Mookerjee, B., Ferrari, A., Mistry, S. & Atweh, G. F. Regulation of phosphoprotein p18 in leukemic cells. Cell cycle regulated phosphorylation by p34cdc2 kinase. J Biol Chem 269,

10312–10318 (1994). CAS  PubMed  Google Scholar  * Marklund, U., Osterman, O., Melander, H., Bergh, A. & Gullberg, M. The phenotype of a “Cdc2 kinase target site-deficient” mutant of

oncoprotein 18 reveals a role of this protein in cell cycle control. J Biol Chem 269, 30626–30635 (1994). CAS  PubMed  Google Scholar  * Kang, W. et al. Stathmin1 plays oncogenic role and is

a target of microRNA-223 in gastric cancer. PLoS One 7, e33919, doi: 10.1371/journal.pone.0033919 (2012). Article  CAS  ADS  PubMed  PubMed Central  Google Scholar  * Rubin, C. I. &

Atweh, G. F. The role of stathmin in the regulation of the cell cycle. Journal of cellular biochemistry 93, 242–250, doi: 10.1002/jcb.20187 (2004). Article  CAS  Google Scholar  * Rowlands,

D. C. et al. Stathmin is expressed by the proliferating hepatocytes during liver regeneration. Clin Mol Pathol 48, M88–92 (1995). CAS  PubMed  PubMed Central  Google Scholar  * Chen, Y. L.

et al. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma. Ann Surg Oncol 20, 4041–4054 (2013). PubMed  Google Scholar  * Fellous, A., Lennon, A. M., Francon,

J. & Nunez, J. Thyroid hormones and neurotubule assembly _in vitro_ during brain development. Eur J Biochem 101, 365–376 (1979). CAS  PubMed  Google Scholar  * Verga Falzacappa, C. et

al. T(3) preserves ovarian granulosa cells from chemotherapy-induced apoptosis. J Endocrinol 215, 281–289 (2012). PubMed  Google Scholar  * Samuels, H. H., Stanley, F. & Casanova, J.

Depletion of L-3,5,3′-triiodothyronine and L-thyroxine in euthyroid calf serum for use in cell culture studies of the action of thyroid hormone. Endocrinology 105, 80–85 (1979). CAS  PubMed

  Google Scholar  * Shih, C. H. et al. Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins. Endocrinology 145, 2804–2814 (2004). CAS  PubMed

  Google Scholar  * Barnes, D. M., Dublin, E. A., Fisher, C. J., Levison, D. A. & Millis, R. R. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new

independent indicator of prognosis? Human pathology 24, 469–476 (1993). CAS  PubMed  Google Scholar  * Liao, C. H. et al. Positive regulation of spondin 2 by thyroid hormone is associated

with cell migration and invasion. Endocr Relat Cancer 17, 99–111 (2010). CAS  PubMed  Google Scholar  Download references ACKNOWLEDGEMENTS This work was supported by grants from Chang-Gung

Memorial Hospital, Taoyuan, Taiwan (BMRP 130, CMRPD180011, 180012, 180013, CMRPD1A0331, CMRPD1A0332, CMRPD1A0333, NMRPD1A0921, 1A0922, NMRPD1A0923, NMRPD1A1231, NMRPD1A1232, NMRPD1A1233) and

from the Ministry of Science and Technology, Taiwan (MOST 100-2320-B-182-029-MY3, 102-2811-B-182-009, 100-2321-B-182-005, 101-2321-B-182-003, 102-2321-B-182-003). AUTHOR INFORMATION AUTHORS

AND AFFILIATIONS * Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Republic of China, Taiwan Yi-Hsin Tseng, Sheng-Ming Wu, Hsiang-Cheng

Chi, Chung-Ying Tsai, Yang-Hsiang Lin, Wei-Chun Chang & Kwang-Huei Lin * Liver Research Center, Chang Gung Memorial Hospital, Taoyuan 333, Linko, Republic of China, Taiwan Ya-Hui Huang 

& Kwang-Huei Lin * Division of Neurosurgery, Chang Gung Memorial Hospital-Linkou & Chang Gung University, Taoyuan 333, Republic of China, Taiwan Tzu-Kang Lin * Department of Nursing,

Chang-Gung University of Science and Technology, Taoyuan 333, Republic of China, Taiwan Ming-Ming Tsai * Molecular Medicine Research Center, Chang Gung University, Taoyuan 333, Republic of

China, Taiwan Ya-Ting Chang * First Cardiovascular Division, Chang Gung Memorial Hospital, Taoyuan 333, Republic of China, Taiwan Wei-Jan Chen Authors * Yi-Hsin Tseng View author

publications You can also search for this author inPubMed Google Scholar * Ya-Hui Huang View author publications You can also search for this author inPubMed Google Scholar * Tzu-Kang Lin

View author publications You can also search for this author inPubMed Google Scholar * Sheng-Ming Wu View author publications You can also search for this author inPubMed Google Scholar *

Hsiang-Cheng Chi View author publications You can also search for this author inPubMed Google Scholar * Chung-Ying Tsai View author publications You can also search for this author inPubMed 

Google Scholar * Ming-Ming Tsai View author publications You can also search for this author inPubMed Google Scholar * Yang-Hsiang Lin View author publications You can also search for this

author inPubMed Google Scholar * Wei-Chun Chang View author publications You can also search for this author inPubMed Google Scholar * Ya-Ting Chang View author publications You can also

search for this author inPubMed Google Scholar * Wei-Jan Chen View author publications You can also search for this author inPubMed Google Scholar * Kwang-Huei Lin View author publications

You can also search for this author inPubMed Google Scholar CONTRIBUTIONS Y.H.T. designed the study, performed and analyzed all experiments, and wrote the manuscript. Y.H.H. performed and

analyzed the promoter assay, and designing of the promoter construction. T.K.L., S.M.W., H.C.C., C.Y.T., M.M.T., and Y.H.L. provided experimental and technical assistance in acquisition of

data. W.C.C. and Y.T.C. performed and analyzed most experiments. W.J.C. supervised the study, and edited the manuscript. K.H.L. designed the study, supervised the study, and wrote the

manuscript. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing financial interests. ELECTRONIC SUPPLEMENTARY MATERIAL SUPPLEMENTARY FIGURE RIGHTS AND PERMISSIONS This

work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons

license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to

reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Tseng, YH., Huang,

YH., Lin, TK. _et al._ Thyroid hormone suppresses expression of stathmin and associated tumor growth in hepatocellular carcinoma. _Sci Rep_ 6, 38756 (2016). https://doi.org/10.1038/srep38756

Download citation * Received: 01 June 2016 * Accepted: 14 November 2016 * Published: 09 December 2016 * DOI: https://doi.org/10.1038/srep38756 SHARE THIS ARTICLE Anyone you share the

following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer

Nature SharedIt content-sharing initiative